Loading...

Portola Pharmaceuticals

DB:0PP
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0PP
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Portola Pharmaceuticals has significant price volatility in the past 3 months.
0PP Share Price and Events
7 Day Returns
9.9%
DB:0PP
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
15.9%
DB:0PP
-5.6%
DE Biotechs
-4.5%
DE Market
0PP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Portola Pharmaceuticals (0PP) 9.9% 12.9% 36.8% 15.9% 46.8% 89%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 0PP outperformed the Biotechs industry which returned -5.6% over the past year.
  • 0PP outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
0PP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Portola Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Portola Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Portola Pharmaceuticals.

DB:0PP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0PP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (8.85%))
1.372
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.37
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.372 * 5.96%)
8.4%

Discounted Cash Flow Calculation for DB:0PP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Portola Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0PP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.4%)
2019 -238.00 Analyst x2 -219.55
2020 -205.00 Analyst x2 -174.45
2021 -91.50 Analyst x2 -71.83
2022 114.00 Analyst x1 82.56
2023 225.00 Analyst x1 150.31
2024 328.36 Est @ 45.94% 202.36
2025 434.18 Est @ 32.23% 246.83
2026 532.42 Est @ 22.63% 279.22
2027 617.12 Est @ 15.91% 298.55
2028 686.25 Est @ 11.2% 306.27
Present value of next 10 years cash flows $1,100.27
DB:0PP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $686.25 × (1 + 0.23%) ÷ (8.4% – 0.23%)
$8,414.46
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,414.46 ÷ (1 + 8.4%)10
$3,755.29
DB:0PP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,100.27 + $3,755.29
$4,855.56
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,855.56 / 68.02
$71.39
DB:0PP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0PP represents 0.88246x of NasdaqGS:PTLA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88246x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 71.39 x 0.88246
€63.00
Value per share (EUR) From above. €63.00
Current discount Discount to share price of €31.76
= -1 x (€31.76 - €63.00) / €63.00
49.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Portola Pharmaceuticals is available for.
Intrinsic value
50%
Share price is €31.76 vs Future cash flow value of €63
Current Discount Checks
For Portola Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Portola Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Portola Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Portola Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Portola Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0PP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.31
NasdaqGS:PTLA Share Price ** NasdaqGS (2019-04-25) in USD $35.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Portola Pharmaceuticals.

DB:0PP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PTLA Share Price ÷ EPS (both in USD)

= 35.99 ÷ -5.31

-6.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Portola Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Portola Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Portola Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:0PP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
50.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Portola Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Portola Pharmaceuticals's assets?
Raw Data
DB:0PP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.33
NasdaqGS:PTLA Share Price * NasdaqGS (2019-04-25) in USD $35.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:0PP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PTLA Share Price ÷ Book Value per Share (both in USD)

= 35.99 ÷ 1.33

27.12x

* Primary Listing of Portola Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Portola Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Portola Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Portola Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Portola Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Portola Pharmaceuticals expected to grow at an attractive rate?
  • Portola Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Portola Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Portola Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0PP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0PP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 50.8%
DB:0PP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 40.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0PP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0PP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 751 211 3
2022-12-31 623 -8 4
2021-12-31 422 -184 -115 5
2020-12-31 250 -220 -212 5
2019-12-31 114 -219 -274 5
DB:0PP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 40 -326 -350
2018-09-30 35 -328 -353
2018-06-30 24 -305 -365
2018-03-31 24 -262 -329
2017-12-31 23 -225 -286
2017-09-30 26 -173 -248
2017-06-30 32 -192 -258
2017-03-31 32 -210 -246
2016-12-31 36 -196 -269
2016-09-30 26 -240 -281
2016-06-30 20 -217 -244
2016-03-31 18 -198 -245

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Portola Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Portola Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0PP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Portola Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.46 2.90 -1.14 3.00
2022-12-31 -0.13 1.50 -2.44 3.00
2021-12-31 -2.37 -1.39 -3.36 2.00
2020-12-31 -2.95 -2.60 -3.59 3.00
2019-12-31 -4.10 -3.80 -4.34 3.00
DB:0PP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.31
2018-09-30 -5.38
2018-06-30 -5.71
2018-03-31 -5.32
2017-12-31 -4.81
2017-09-30 -4.33
2017-06-30 -4.55
2017-03-31 -4.35
2016-12-31 -4.76
2016-09-30 -5.05
2016-06-30 -4.45
2016-03-31 -4.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Portola Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Portola Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Portola Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Portola Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Portola Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Portola Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Portola Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Portola Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Portola Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Portola Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 40.13 -350.22 151.16
2018-09-30 34.64 -353.46 137.45
2018-06-30 24.29 -365.09 127.51
2018-03-31 24.06 -328.55 107.63
2017-12-31 22.55 -286.09 91.11
2017-09-30 26.44 -248.15 77.07
2017-06-30 31.93 -258.10 61.79
2017-03-31 32.37 -245.79 58.51
2016-12-31 35.50 -269.04 58.24
2016-09-30 26.23 -281.31 56.26
2016-06-30 19.82 -243.58 52.75
2016-03-31 17.97 -244.57 44.62
2015-12-31 12.07 -226.51 38.87
2015-09-30 10.07 -199.66 34.94
2015-06-30 9.58 -180.29 31.29
2015-03-31 9.61 -153.31 27.32
2014-12-31 9.63 -137.13 23.55
2014-09-30 9.27 -122.93 21.36
2014-06-30 9.61 -105.69 18.84
2014-03-31 9.80 -95.94 17.61
2013-12-31 10.53 -83.35 15.42
2013-09-30 10.43 -58.61 13.38
2013-06-30 8.41 -51.55 12.35
2013-03-31 72.67 -17.08 11.70
2012-12-31 72.04 0.00 11.47
2012-09-30 109.60 0.42 12.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Portola Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Portola Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Portola Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Portola Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Portola Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Portola Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Portola Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Portola Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Portola Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Portola Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Portola Pharmaceuticals Company Filings, last reported 3 months ago.

DB:0PP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 90.57 215.36 316.96
2018-09-30 166.93 211.14 369.98
2018-06-30 220.06 206.21 435.89
2018-03-31 310.17 107.40 408.57
2017-12-31 349.49 104.82 463.16
2017-09-30 428.39 104.89 569.13
2017-06-30 113.37 101.74 269.70
2017-03-31 163.73 98.29 318.20
2016-12-31 192.69 49.82 318.77
2016-09-30 241.30 0.00 274.60
2016-06-30 323.91 0.00 353.56
2016-03-31 373.54 0.00 420.98
2015-12-31 430.32 0.00 444.20
2015-09-30 322.91 0.00 355.97
2015-06-30 368.03 0.00 401.51
2015-03-31 418.98 0.00 391.41
2014-12-31 347.80 0.00 309.27
2014-09-30 209.23 0.00 225.20
2014-06-30 241.90 0.00 227.93
2014-03-31 269.19 0.00 261.43
2013-12-31 296.34 0.00 268.67
2013-09-30 197.95 0.00 174.78
2013-06-30 214.60 0.00 207.60
2013-03-31 109.08 0.00 116.89
2012-12-31 125.71 0.00 131.27
2012-09-30 138.79 0.00 131.07
  • Portola Pharmaceuticals's level of debt (237.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 237.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Portola Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Portola Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.3% each year.
X
Financial health checks
We assess Portola Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Portola Pharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Portola Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Portola Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Portola Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Portola Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Portola Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0PP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0PP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Portola Pharmaceuticals has not reported any payouts.
  • Unable to verify if Portola Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Portola Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Portola Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Portola Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Portola Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Portola Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Portola Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Portola Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Garland
AGE 49
TENURE AS CEO 0.5 years
CEO Bio

Mr. J. Scott Garland, MBA has been President, Chief Executive Officer and Director at Portola Pharmaceuticals Inc. since October 08, 2018. He was President of Relypsa, Inc., from March 31, 2017 to October 1, 2018. Mr. Garland served as Chief Commercial Officer and Senior Vice President at Relypsa, Inc. since November 2014 until March 31, 2017. Mr. Garland served as an Executive Vice President and Chief Commercial Officer at Exelixis, Inc. from October 25, 2011 to October 2014. Mr. Garland oversaw the commercial functions of marketing, sales and commercial operations and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications. Prior to joining Exelixis, from April 2002 to October 2011, Mr. Garland held positions at Genentech, Inc. Mr. Garland is a seasoned biotechnology and pharmaceutical industry veteran with more than 20 years of sales, marketing and commercialization experience in the pharmaceutical and biopharmaceutical industry as well as his extensive management experience at publicly-traded companies biopharmaceutical companies. Since 2009, Mr. Garland served as vice president of Genentech's Avastin franchise, the largest product at Genentech and one of the top five oncology products in the world, where he led the U.S. sales and marketing efforts for the drug. At Genentech, he served as vice president, hematology marketing and sales, overseeing the Rituxan franchise and as a director on the Tarceva franchise. Before Genentech, he held several positions in sales and marketing at Amgen from July 1997 to April 2002. He also spent multiple years at Merck & Co., Inc., including as professional sales representative from July 1991 to July 1995. He serves as an Independent Director at Karyopharm Therapeutics Inc. since November 03, 2014. Mr. Garland received his MBA from Duke University's Fuqua School of Business and his BA Degree from California Polytechnic University (San Luis Obispo).

CEO Compensation
  • Insufficient data for J. to compare compensation growth.
  • Insufficient data for J. to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Portola Pharmaceuticals management team in years:

2.7
Average Tenure
54
Average Age
  • The tenure for the Portola Pharmaceuticals management team is about average.
Management Team

Mardi Dier

TITLE
Executive VP
COMPENSATION
$2M
AGE
54
TENURE
12.7 yrs

Bill Lis

TITLE
Consultant
COMPENSATION
$5M
AGE
54
TENURE
0.7 yrs

John Curnutte

TITLE
Executive VP and Head of Research & Development
COMPENSATION
$2M
AGE
66
TENURE
8.2 yrs

J. Garland

TITLE
President
AGE
49
TENURE
0.5 yrs

Cara Miller

TITLE
Vice President of Investor Relations and Corporate Communications

John Moriarty

TITLE
Executive VP
AGE
50
TENURE
1.1 yrs

Jeet Mahal

TITLE
Vice President of Business Development
TENURE
6.3 yrs

Mark Gossett

TITLE
Senior Vice President of Global Marketing

Randy St. Laurent

TITLE
Vice President of Sales
TENURE
4.3 yrs

Ernie Meyer

TITLE
Executive VP & Chief Human Resources Officer
AGE
54
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Portola Pharmaceuticals board of directors in years:

7.1
Average Tenure
62.5
Average Age
  • The tenure for the Portola Pharmaceuticals board of directors is about average.
Board of Directors

Hollings Renton

TITLE
Chairman
COMPENSATION
$321K
AGE
71
TENURE
9.1 yrs

J. Garland

TITLE
President
AGE
49
TENURE
0.5 yrs

H. Wolff

TITLE
Independent Director
COMPENSATION
$289K
AGE
69
TENURE
11.4 yrs

John Johnson

TITLE
Independent Director
COMPENSATION
$309K
AGE
60
TENURE
5.1 yrs

Jeff Bird

TITLE
Independent Director
COMPENSATION
$285K
AGE
57
TENURE
15.4 yrs

Charles Esmon

TITLE
Member of Scientific Advisory Board

Art Weiss

TITLE
Member of Scientific Advisory Board

David Ginsburg

TITLE
Member of Scientific Advisory Board
AGE
65

Frank McCormick

TITLE
Member of Scientific Advisory Board
AGE
68

Laura Brege

TITLE
Independent Director
COMPENSATION
$285K
AGE
60
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Aug 18 Buy Jeffrey Bird Individual 21. Aug 18 23. Aug 18 390,000 €23.02 €8,706,862
X
Management checks
We assess Portola Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Portola Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Details
Name: Portola Pharmaceuticals, Inc.
0PP
Exchange: DB
Founded: 2003
$2,183,743,346
68,018,098
Website: http://www.portola.com
Address: Portola Pharmaceuticals, Inc.
270 East Grand Avenue,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PTLA Common Stock Nasdaq Global Select US USD 22. May 2013
DB 0PP Common Stock Deutsche Boerse AG DE EUR 22. May 2013
Number of employees
Current staff
Staff numbers
324
Portola Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:07
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.